Júlia Companys-Alemany, Andreea L Turcu, Aina Bellver-Sanchis, Maria I Loza, José M Brea, Anna M Canudas, Rosana Leiva, Santiago Vázquez, Mercè Pallàs, Christian Griñán-Ferré
Alzheimer's disease (AD) is the leading cause of dementia. Non-competitive N-Methyl-D-aspartate (NMDA) receptor antagonist memantine improved cognition and molecular alterations after preclinical treatment. Nevertheless, clinical results are discouraging. In vivo efficacy of the RL-208, a new NMDA receptor blocker described recently, with favourable pharmacokinetic properties was evaluated in Senescence accelerated mice prone 8 (SAMP8), a mice model of late-onset AD (LOAD). Oral administration of RL-208 improved cognitive performance assessed by using the three chamber test (TCT), novel object recognition test (NORT), and object location test (OLT)...
March 22, 2020: Pharmaceutics